Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity

Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity

Sialic acid-binding Immunoglobulin-like lectin-9 (Siglec-9) is a glyco-immune negative checkpoint expressed on several immune cells. Siglec-9 exerts its inhibitory effects by binding to sialoglycan ligands expressed on cancer cells, enabling them to evade immunosurveillance. We developed a panel of...

Full description

Bibliographic Details
Main Authors: Hyeree Choi, Michelle Ho, Opeyemi S. Adeniji, Leila Giron, Devivasha Bordoloi, Abhijeet J. Kulkarni, Alfredo Perales Puchalt, Mohamed Abdel-Mohsen, Kar Muthumani
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Oncology
Subjects:
human Siglec 9
NK cell
monoclonal antibodies
ovarian cancer
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.778989/full

Similar Items

Similar Items